Does Ozempic cause depression or kill your happiness?

What's this video probably claiming?

Based on the caption "Ozempic is ruining my happiness," this creator is almost certainly describing some version of emotional blunting, anhedonia, or mood changes they attribute to semaglutide. This is one of the more persistent personal narratives circulating in GLP-1 content right now. The creator may be describing a loss of enjoyment in food, social activities, or life in general, which some users frame as the drug "taking away" pleasure. They might also be referencing reduced motivation, flat affect, or what some people loosely call depression. These are real experiences being reported by real patients. The question is whether semaglutide is actually causing them, whether this is a known pharmacological effect, or whether weight loss itself, caloric restriction, or pre-existing conditions are the actual drivers. Emotional experiences on TikTok tend to collapse that nuance fast.

What does the science actually show?

The clinical trial data on semaglutide and mood is genuinely mixed, and the honest answer is that we do not have a clean verdict yet. The SUSTAIN and STEP trial programs, which formed the backbone of semaglutide's regulatory approval, did not find statistically significant increases in depression or suicidal ideation compared to placebo. However, the FDA added a pharmacovigilance request in 2023 after the EMA flagged reports of suicidal thoughts across GLP-1 medications. A 2024 observational study by Tseng and colleagues in Nature Medicine analyzed over 240,000 patients and found semaglutide users had a lower risk of new-onset depression compared to non-users. But observational data has confounders. Separately, animal research has shown GLP-1 receptors are expressed in reward-related brain regions including the nucleus accumbens and ventral tegmental area, which means the drug plausibly affects dopamine signaling. That is not proof of harm, but it is a legitimate biological mechanism worth watching.

Where does the social media noise diverge from clinical reality?

The biggest problem with this genre of content is that anhedonia from caloric restriction is extremely well-documented and has nothing to do with semaglutide specifically. When you eat significantly less, dopamine and serotonin signaling tied to food reward drops. People who have used food as emotional regulation for years suddenly lose that tool, and they feel worse. That is not a drug side effect in the traditional sense. It is a psychological adjustment to major behavioral change. TikTok creators rarely make that distinction. There is also a meaningful difference between "I stopped enjoying eating pizza" and "I have clinical depression." GLP-1 medications dramatically reduce food reward, which is partly how they work. Some patients experience that as freedom. Others experience it as loss. Both responses are real. A 2023 paper by Blundell and colleagues in Obesity Reviews discussed this reward-reduction mechanism directly, noting it complicates patient-reported quality of life assessments in ways that raw depression scales do not capture.

What should you actually know?

If you are on semaglutide or tirzepatide and feeling emotionally flat, that experience deserves clinical attention, not dismissal. Tell your prescriber. Mood changes during significant weight loss are common regardless of the mechanism, and anyone with a history of depression or anxiety should be monitored more closely when starting a GLP-1 medication. The FDA's 2023 safety review ultimately concluded available evidence did not confirm a causal link between GLP-1 drugs and suicidality, but the agency continues monitoring. What the data does support is that for most patients, semaglutide is associated with improvements in depression scores over time, likely connected to weight loss and metabolic improvements. The minority who experience worsening mood are real, they are not making it up, and they should not be ignored. But a TikTok caption is not a clinical signal. It is a data point of one, framed for engagement.